Sector News

Dr Susanne Fiedler takes over as CEO of MSD Germany

January 28, 2016
Life sciences

MSD Germany has appointed Dr Susanne Fiedler as CEO to take over from Hanspeter Quodt, who steps after seven years in the post.

Dr Fielder first joined the German operations of Merck & Co in 1997, when she took up a role in market research.

She then moved to market, initially as a product manager and later as a marketing manager and then a business unit head with responsibility for a number of MSD products.

Since then Dr Fielder has served in the US, where MSD operates at Merck & Co, as global brand leader for the diabetes treatments Januvia and Janumet, before taking up a Sydney-based role as managing director of MSD Australia and New Zealand.

She will officially take on her new role on 1 February, when Quodt moves to a new European level position.

Source: PMLive

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach